Welcome to the Wet AMD & DME Drug Development Summit
Running virtually for 2021, the inaugural Wet AMD & DME Drug Development Summit comes at a critical juncture, as the research community progresses novel drug candidates targeting angiogenesis-driven disease and a pandemic further exposes the current treatment limitations for a global aging population.
Join this dedicated industry forum, to network online and learn from senior leaders of discovery, translational sciences, and clinical development from the likes of Boehringer Ingelheim, Doheny Eye Institute, Aerpion Therapeutics, Genentech, Ocugen and more to address the specific challenges for the biopharmaceutical and biotechnology in its efforts to bring long-lasting treatments which reduce clinical burden and can be commercialized to become the new standard-of-care in this vast ophthalmology indication.
Navigate across 3 jam-packed days including interactive workshops exploring clinical biomarkers for testing drugs in patients and developing preclinical models to predict human disease and efficacy of a drug.
Who Attended in 2021?
Expert Speakers Include:
Feedback from the Wet AMD & DME Drug Development Summit:
“Outstanding program with diverse and salient presentations regarding advances in the treatment of Wet AMD and DME”
CEO, ForwardVue Pharma
“Comprehensive and informative”
Chief Medical Officer, Chair-Cell Biology of the Faculty of Science, Radboud University Nijmegen